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Purpose: To determine the indications and the diagnostic accuracy of vacuum-assisted breast 
biopsy (VABB) under ultrasonographic (US) guidance based on a 10-year period of clinical use.
Methods: This was a retrospective analysis of 2,920 breast lesions in 2,477 consecutive patients 
who underwent US-guided VABB between February 2002 and December 2011. The proportions 
of each indication for VABB were analyzed as well as the trend of its use over divided time 
periods. Histopathological diagnosis and the malignancy rate of the lesions with VABB were 
analyzed. A comparison of the pathological diagnosis of VABB and the gold standard diagnosis 
revealed the false negative rate, the underestimation rate, and the agreement rate.
Results: Palpable lesions (44.4%), low-suspicion lesions (15.7%), high-risk lesions (12.4%), and 
calcifications (10.3%) were the most common indications for US-guided VABB. The malignancy 
rate of lesions submitted to VABB was 5.4%. The false negative rate was only 0.1%, while the 
underestimation rate of high-risk lesions and ductal carcinoma in situ was 3.1% and 13.8%, 
respectively, with a 98.7% agreement rate. Among 1,512 therapeutic VABB cases, 84.9% 
showed no residual or recurrent lesions on long term follow-up US for more than a year. 
Complications occurred in 1% of the patients without need for surgical intervention. 
Conclusion: US-guided VABB is an accurate and safe method that can help decision-making 
in the diagnostic process and can be an alternative for excisional surgery in some therapeutic 
circumstances. 
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Introduction
Vacuum-assisted breast biopsy (VABB) was introduced in the mid-1990s with the advent of large-
lumen cannula [1], as a technique enabling the removal of all visible lesions while potentially 
reducing false negative rates and underestimation rates [2,3]. VABB allows faster acquisition of 
larger tissue volumes than core needle biopsy (CNB) as it permits retrieval of contiguous tissue 
specimens by using a single insertion with a larger gauge probe, thereby resulting in a more reliable 
histological diagnosis [4]. The reliability of histopathological diagnosis after VABB is known to be 
nearly equivalent to that of open biopsy in some studies [5]. VABB also allows accurate diagnosis and 
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complete image-guided removal of presumed benign breast lesions 
[4,6]. Compared to a 14-gauge CNB, VABB with an 8-gauge needle 
(for lesions that are 1.3-3.0 cm in the greatest dimension) or an 
11-gauge needle (for lesions that are 1.0 cm or less in the greatest 
dimension) offers greater reliability, fewer complications, and more 
satisfactory cosmetic outcomes [7-10]. 
VABB is often used for diagnostic purposes for palpable or non-
palpable nodular breast lesions, particularly in cases of mismatch 
between imaging reports and histological diagnosis after CNB 
or in breast lesions with radiologically suspicious findings, and 
in breast lesions that are too small (<5 mm) for a representative 
biopsy by CNB [4,10,11]. VABB is also therapeutically performed 
for symptomatic lesions not suspicious for carcinoma, such as 
fibroadenoma or recurrent cysts, with the aim of complete removal 
of all visible lesions [4]. There have been attempts to make 
recommendations for the use of VABB under ultrasonographic 
(US) guidance [4,12], but it is not yet clear when VABB should be 
performed or the diagnostic accuracy of its performance. The aim of 
this study was to determine the indications and diagnostic accuracy 
of VABB under ultrasonographic guidance, based on 10 years of 
experience in a single center, so that the appropriate timing and 
circumstances of US-guided VABB use can be further clarified in 
clinical practice.
Materials and Methods
Patient Selection
This was a retrospective single-center study. This study was approved 
by our hospital’s Institutional Review Board, and informed consent 
was waived because of its retrospective design. From February 
2002 to December 2011, 2,920 lesions of 2,477 patients who had 
undergone US-guided VABB in our institution were included in this 
study. 
US-guided VABB
By means of a vacuum-assisted device (Mammotome, Ethicon-
Endosurgery, Cincinnati, OH, USA) with an 8-gauge or an 11-gauge 
probe under the guidance of high-resolution US with 5-10-MHz 
or 5-12-MHz linear-array transducers (HDI 5000, Philips Advanced 
Technology Laboratories, Bothell, WA, USA; Logic 9, GE Medical 
Systems, Milwaukee, WI, USA; or iU22, Philips Medical Systems, 
Bothell), the VABB procedure was performed as described by 
Kim et al. [13]. The VABB procedure was performed by one of 24 
radiologists with 2-11 years of experience in breast imaging and 
US-guided biopsy.
Indications for US-guided VABB
Indications for US-guided VABB were retrospectively classified into 9 
categories as follows, with 7 indications for diagnostic purposes and 
2 indications for therapeutic purposes. 
Indications for diagnostic VABB included calcifications, complex 
and intraductal lesions, discordant benign lesions, growing lesions, 
high-risk lesions on previous CNB, low-suspicion lesions, and 
non-mass lesions. Calcifications were mainly microcalcifications 
delineated by US. Discordant benign lesions were defined as lesions 
suspicious for malignancies at imaging, but which demonstrated 
benign pathological results after CNB [14]. High-risk lesions on 
previous CNB included atypical ductal hyperplasia (ADH), lobular 
neoplasia (atypical lobular hyperplasia and lobular carcinoma in 
situ), phyllodes tumors including fibroepithelial lesions, papillary 
lesions, mucocele-like lesions, complex sclerosing lesions, and radial 
scars [15-19]. Low-suspicion lesions were breast lesions that 
had findings that presented a low suspicion of malignancy on US 
imaging, such as hypoechogenicity or ill-defined margins, except for 
lesions with microcalcifications and complex cystic or intraductal 
lesions. Non-mass lesions were breast lesions that showed diffuse 
heterogeneous echogenicity or parenchymal distortion, without a 
definite focal mass. 
Indications for therapeutic VABB included palpable lesions and 
lesions that the patients wished to have removed. Palpable lesions 
were those that were removed by VABB with the aim of complete 
image-guided excision but did not have any of the findings above. 
Breast lesions that were excised by VABB because of a patient’s 
desire to have the breast lesion removed even if the lesion did 
not show any of the above features, were classified into the last 
indication. The proportions of each indication for VABB were 
analyzed as well as their chronological trend of occurrence.
Histopathological Diagnosis 
Histopathological diagnosis and the malignancy rate of the lesions 
with VABB were analyzed, as well as those of the lesions with 
previous CNB and excisional surgery afterwards. Histopathological 
diagnosis of the breast lesions were classified into four categories: 
benign, high-risk, ductal carcinoma in situ (DCIS), and invasive 
cancer. The diagnostic accuracy of US-guided VABB was assessed 
using a 4×4 table method introduced by Burbank and Parker [20]. 
We compared the pathological results of US-guided VABB and the 
gold standard results, which were obtained from surgical excision or 
long-term US follow-up. The gold standard results were pathological 
results of surgical excision in cases that had undergone surgery, and 
long-term US follow-up showing no interval change or no evidence 
of recurrence for more than 1 year in the case of benign or high-risk 
lesions that had not undergone surgery were considered as benign 
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gold standard result.
Subsequently, we calculated the agreement rate, the high-risk 
underestimation rate, the DCIS underestimation rate, and the false-
negative rate of US-guided VABB. High-risk underestimation was 
considered when high-risk group lesions diagnosed by VABB were 
upgraded to DCIS or invasive cancer after subsequent surgery. The 
underestimation rate was calculated for all high-risk lesions (ADH 
lesions and non-ADH high-risk lesions). The DCIS underestimation 
rate was defined as the proportion of lesions diagnosed as DCIS 
by VABB that were upgraded to invasive carcinoma after surgical 
excision. The false negative rate was defined as the proportion 
of all breast cancers (invasive cancer and DCIS) diagnosed by 
surgery or on follow-up biopsy, after a benign diagnosis on US-
guided VABB. The agreement rate was defined as the proportion of 
lesions that were not classified as DCIS underestimation, high-risk 
underestimation, or false-negative diagnosis [21].
Post-Biopsy Management and Follow-up 
For patients with breast lesions diagnosed as DCIS or invasive cancer, 
or as the high-risk group, surgical excision was recommended. 
Otherwise, patients were followed up with breast US at a certain 
interval. A follow-up US at 6 months after VABB was recommended 
for every patient in order to evaluate any complications that 
occurred after the procedure as well as to evaluate residual or 
recurrent lesions. For the high-risk group patients who did not 
undergo surgery, a follow-up period of 6 months was recommended 
for up to 2 years after the initial diagnosis. The complications of the 
VABB procedure were recorded at the time of the procedure and at 
follow-up if any were newly discovered.
Results
The average age of the 2,477 patients was 39 years (range, 11 to 
81 years), and the average size of the 2,920 lesions was 14.4 mm 
(range, 3 to 80 mm). The pathological results of US-guided VABB in 
the 2,920 breast lesions are summarized in Table 1. Out of the 2,920 
breast lesions submitted to VABB, the pathological diagnosis was 
benign in 2,302 lesions (78.84%), high-risk group in 460 lesions 
(15.75%), DCIS in 122 lesions (4.18%), and invasive cancer in 36 
lesions (1.23%). 
The overall indications for VABB and the chronological trend over 
divided intervals are shown in Table 2. Palpable lesions were the 
most common indication overall and for every time period from 
2002 to 2011. Suspicious lesions and high-risk lesions have been 
common indications for VABB since 2006. Among the 363 high-
risk lesions that were diagnosed by previous CNB, 338 lesions were 
papillary lesions, 9 lesions were ADH, 7 lesions were mucocele-like 
lesions, 6 lesions were phyllodes tumors, including fibroepithelial 
lesions, and 3 lesions were radial scars.
Breast lesions were classified according to the US Breast Imaging-
Reporting and Data System (BI-RADS) by a US examination 
conducted before VABB. The BI-RADS category and positive 
predictive values (PPV) of the breast lesions according to the 
indications of US-guided VABB are summarized in Table 3. High 
PPVs of lesions with calcifications, non-mass lesions, and discordant 
benign lesions are related to the higher BI-RADS category. 
Pathological results and the malignancy rate of breast lesions 
according to the indications of VABB are shown in Table 4. The 
malignancy rate of all lesions submitted to VABB was 5.4%. 
Among the 2,920 lesions of 2,477 patients with histological 
Table 1. Pathological results of ultrasonographic-guided 
vacuum-assisted breast biopsy in 2,920 lesions
Finding No. of lesions
Benign 2,302
  Fibroadenoma 919
  Fibrocystic change 558
  Fibroadenomatous hyperplasia 379
  Adenosis 166
  Fibrosis 114
  Ductal epithelial hyperplasia 81
  Columnar cell change 35
  Inflammation 5
  Othersa) 45
High-risk 460
  Atypical ductal hyperplasia 30
  Non-atypical ductal hyperplasia 430
    Papillary lesion 355
    Phyllodes tumor 53
    Mucocele-like lesion 15
    Radial scar 7
Malignant 158
  Ductal carcinoma in situ 122
  Invasive cancer 36
    Invasive ductal carcinoma 28
    Invasive lobular carcinoma 2
    Mucinous carcinoma 1
    Tubular carcinoma 1
    Neuroendocrine carcinoma 1
    Leukemia 1
    Metastasis to breast 2
a) Others included inflammation, diabetes mastopathy, epidermal cyst, galactocele, 
hamartoma, lobular hyperplasia, and xanthogranulomatous mastitis. 
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Table 3. BI-RADS category and positive predictive values of breast lesions according to indications of ultrasonographic-guided VABB
                          Variable
BI-RADS category
PPV (%) a)
1, 2 3 4a 4b 4c 5
Palpable lesions (n=1,296) 6 1,259 27 4 0 0 6.6 (2/31)
Low-suspicion lesions (n=458) 0 0 444 14 0 0 1 (5/458)
High-risk lesions (n=363) 1 100 238 13 9 2 3 (7/262)
Calcifications (n=302) 0 31 164 41 44 22 41 (111/271)
Patient's desire (n=216) 9 207 0 0 0 0 0 (0/0)
Complex and intraductal lesions (n=112) 2 48 57 3 2 0 3 (2/62)
Discordant benign lesions (n=79) 0 0 8 42 16 13 12.7 (10/79)
Non-mass lesions (n=65) 1 19 29 10 3 3 24 (11/45)
Growing lesions (n=29) 0 19 10 0 0 0 0 (0/10)
Total (n=2,920) 19 1,691 1,011 99 73 27 12.2 (148/1,210)
BI-RADS, Breast Imaging-Reporting and Data System; VABB, vacuum-assisted breast biopsy; PPV, positive predictive value.
a) The number of breast lesions diagnosed as malignant (invasive cancer or ductal carcinoma in situ) with VABB divided by the number of lesions belonging to ultrasonographic-
BI-RADS categories 4 and 5. 
diagnosis after VABB, 367 lesions of 309 patients were removed 
by surgery. The final pathological diagnosis after surgery revealed 
benign pathology in 128 lesions, high-risk pathology in 84 lesions, 
DCIS in 106 lesions, and invasive cancer in 49 lesions. 1,784 lesions 
were breast lesions that underwent US follow-up and showed no 
interval change or no evidence of recurrence for more than 1 year 
(i.e., benign diagnosis by the gold standard). Therefore, the gold 
standard diagnosis revealed benign diagnoses in 1,912 lesions, 
high-risk pathology in 84 lesions, DCIS in 106 lesions, and invasive 
cancer in 49 lesions, as shown in Table 5. 
The false negative rate of US-guided VABB was 0.1% (2/1,620). 
False negative results were found for 2 lesions that showed benign 
pathology at VABB but were finally confirmed as DCIS after surgery. 
Both cases were initially submitted to VABB due to suspicious 
microcalcifications, but specimen mammography taken after US-
guided VABB showed no or insufficient calcification, and the 
pathological diagnosis was benign at VABB. VABB results in these 
patients were considered discordant. Immediate surgical excision 
for a definite pathological diagnosis was recommended, and surgery 
confirmed these lesions as DCIS.
The high-risk underestimation rate was 3.1% (12/389), while 
the ADH underestimation rate was 23.3% (7/30) and the non-ADH 
high-risk lesion underestimation rate was 1.4% (5/359). The DCIS 
underestimation rate was 13.8% (15/109). The agreement rate was 
98.7% (2,124/2,151).
In two cases of invasive cancer confirmed at VABB, the final 
pathological diagnosis after surgical excision was DCIS, probably 
because the VABB procedure removed the entire invasive cancer 
component. In one case, invasive cancer diagnosed by VABB 
showed benign pathology without any evidence of carcinoma at 
Table 2. Indications for ultrasonographic-guided vacuum-assisted breast biopsy (VABB) by time period 
Indication of VABB Overall 2002-2005 2006-2008 2009-2011
Palpable lesions 1,296 (44.4) 414 (58.8) 446 (42.3) 436 (37.6)
Low-suspicion lesions 458 (15.7) 45 (6.4) 179 (17.0) 234 (20.2)
High-risk lesions 363 (12.4) 43 (6.1) 155 (14.7) 165 (14.2)
Calcifications 302 (10.3) 72 (10.2) 102 (9.7) 128 (11.0)
Patient's desire 216 (7.4) 86 (12.2) 70 (6.6) 60 (5.2)
Complex and intraductal lesions 112 (3.8) 14 (2.0) 37 (3.5) 61 (5.3)
Discordant benign lesions 79 (2.7) 9 (1.3) 40 (3.8) 30 (2.6)
Non-mass lesions 65 (2.2) 20 (2.8) 17 (1.6) 28 (2.4)
Growing lesions 29 (1.0) 1 (0.1) 9 (0.9) 19 (1.6)
Total 2,920 704 1,055 1,161
Values are presented as number (%).
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surgery afterwards due to complete remission after neoadjuvant 
chemotherapy. 
Among 1,512 breast lesions that underwent VABB for therapeutic 
purposes (i.e., indications for VABB being palpable lesions and the 
patient’s desire), 105 lesions underwent surgery and 910 lesions 
underwent follow-up US for more than a year without surgical 
excision. Among the 910 lesions that underwent follow-up US 
for more than a year, 773 lesions (84.9%) showed no residual 
or recurrent lesions and 116 lesions (12.7%) showed minimal 
residual lesions without remarkable changes through follow-up. 
The remaining 21 lesions (2.3%) had recurred lesions that showed 
probably benign US findings. 
Complications after VABB occurred in 28 patients (1%). 
Hematoma developed in 24 patients after VABB, which were seen as 
resolved on follow-up US. Post-biopsy bleeding persisted for a while 
in 3 patients, but the bleeding stopped after manual compression. 
One patient complained of severe pain after the VABB procedure, 
but this soon resolved itself.
Discussion
Data collected from a 10-year period at our hospital showed that 
US-guided VABB is useful for various diagnostic and therapeutic 
purposes. VABB allows a fast acquisition of a large tissue volume 
as compared to CNB, resulting in a more reliable histopathological 
diagnosis after biopsy and complete image-guided removal of 
breast lesions. Thus far, indications for performing VABB have not 
been clarified in the literature, irrespective of its proven usefulness. 
Therefore, we tried to classify indications for VABB, analyze 
pathological results according to these indications, and suggest a 
guideline for the VABB procedure.
Over the past 10 years, palpable lesions have been the most 
common indication, and for every time period as well. A palpable 
breast lesion is the most common chief complaint in itself for 
patients visiting breast clinics; therefore, it might have been the 
most common reason for performing VABB. Low-suspicion lesions, 
high-risk lesions, and calcifications were the next most common 
indications for VABB. VABB was performed in these lesions for a 
definite diagnosis as these lesions were suspicious for malignancy 
with or without previous CNB results. 
High-risk lesions diagnosed after CNB are known to show a 
significant underestimation rate. In the past, CNB was, therefore, 
followed by an open diagnostic biopsy, while, in the present, it is 
being replaced by VABB [4,5]. In papillary lesions diagnosed by CNB, 
Table 4. Pathological results and malignancy rates of breast lesions according to indications of ultrasonographic-guided vacuum-
assisted breast biopsy
Variable Total Benign High-risk group Ductal carcinoma in situ Invasive cancer Malignancy rate (%)
Palpable lesions 1,296 1,220 70 3 3 0.5
Suspicious lesions 458 419 34 4 1 1.1
High-risk lesions 363 83 272 7 1 2.2
Calcification 302 163 28 96 15 36.8
Patient's desire 216 206 10 0 0 0
Complex and intraductal lesions 112 80 30 1 1 1.7
Discordant benign lesions 79 60 9 3 7 12.7
Non-mass lesions 65 45 5 8 7 18.5
Growing lesions  29 26 2 0 1 3.4
Total  2,920 2,302 460 122 36 5.4
Table 5. Comparison of pathological results of 2,151 US-guided VABB with gold standard diagnoses confirmed by subsequent surgery 
or follow-up US for more than 1 year 
US-guided VABB
Gold standard
Invasive cancer Ductal carcinoma in situ High-risk lesion Benign
Invasive cancer 30 2 0 1
Ductal carcinoma in situ 15 94 0 0
High-risk lesion 4 8 54 323
Benign 0 2 30 1,588
US, ultrasonography; VABB, vacuum-assisted breast biopsy.
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recurrence rates (regrowth or residual) of benign breast lesions after 
excision have been reported to range from 3% to 39% in previous 
studies [26-30]. In our study, therapeutic VABB was performed for 
breast lesions not suspicious for carcinoma because of palpable 
lesions or the desire of individual patients. Image-guided complete 
excision was achieved in 84.9% of breast lesions without residual 
lesions or recurrence on long-term follow-up US for more than 
a year, while there were minimal residuals in 12.7% of them on 
follow-up. Ultrasonographically visible recurrent lesions were noted 
in only 2.3% that even showed probably benign US findings. 
Therapeutic VABB for complete excision of palpable breast lesions 
or conducted due to the patient’s desire to remove the breast lesion 
seems to be a suitable method that is safe and effective.
This study has some limitations. First, classifying indications 
for performing VABB could lack consistency as there was often 
more than one reason for conducting VABB in a patient. For 
example, a patient could have a palpable breast lesion that shows 
microcalcifications on US. We tried to set an order of priority for 
classifying these lesions. Second, the use of US-guided VABB 
could vary between institutions. Our institution has breast imaging 
radiologists with long-term experience with breast US and long-
term clinical experience with US-guided VABB. Therefore, US was 
performed by skilled professionals, and the decision of whether or 
not to perform US-guided VABB could be systematic, with intra- and 
interdisciplinary conferences. However, for institutions that lack VABB 
experience, an investigator’s qualification is mandatory to obtain 
acceptable false negative and underestimation rates with relatively 
few complications from the procedure. Third, for breast lesions that 
did not undergo surgical excision, a definitive pathological diagnosis 
could not be achieved. Even if the lesions showed no evidence of 
recurrence for a US follow-up of 1 year, a change could be possible 
afterwards.
In conclusion, US-guided VABB is an accurate and safe method 
that can help the decision-making of the diagnostic process and 
can be an alternative for excisional surgery in some therapeutic 
circumstances. 
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US-guided large-lumen VABB (8-gauge) has been proven to be an 
alternative to surgical excision for reliable histological diagnosis 
with image-guided complete resection [13,22,23]. In our institution, 
papillary lesions diagnosed by CNB were a particularly common 
indication for VABB for reliable histological diagnosis with a low 
underestimation rate of 1.7%. Non-ADH high-risk lesions including 
papillary lesions, phyllodes tumors, and radial scars showed an 
acceptable underestimation rate of 1.4%. 
On the other hand, thus far, ADH lesions diagnosed by CNB have 
usually been removed by open surgery because of a lack of sufficient 
evidence on whether it is suitable for excision by VABB alone [4]. 
The ADH underestimation rate of VABB, in our study, was 23.3% 
(7/30), still suggesting that histological underestimation should be 
considered for ADH at VABB. Even image-guided complete removal 
of ADH lesions cannot replace surgical excision as reported in the 
previous literature [5,23]. 
Indications classif ied as calcif ication lesions contained 
microcalcifications, and those that showed malignant pathological 
diagnosis after VABB were mostly DCIS with microcalcifications. 
Non-mass lesions had heterogeneous echogenicity or distortion 
of breast parenchyma on US, which created difficulties in the 
acquisition of a representative biopsy by CNB as the lesions were 
broad with distinct margins. A reliable pathological diagnosis 
was still needed for non-mass lesions because infiltrative breast 
cancer could not be ruled out; therefore, VABB was performed for 
diagnostic purposes. The non-mass lesions that were pathologically 
confirmed as malignancy at VABB were confirmed as DCIS, invasive 
carcinoma, and even other pathology such as leukemia involvement 
or metastasis from signet ring cell stomach cancer. Discordant 
lesions have cancer rates reported to be up to 50% for US-guided 
14-gauge CNBs [14]; therefore, surgical biopsy has been performed 
for repeat biopsy. However, in our study, VABB played an alternative 
role to surgical excision in order to obtain a definitive histological 
diagnosis in some of the discordant benign lesions, a method that 
has been suggested in recent reports [14,24].
The DCIS underestimation rate was 13.8%, which was calculated 
from 15 cases that showed DCIS in VABB and invasive carcinoma at 
subsequent surgical excision. A majority of the underestimated cases 
contained suspicious microcalcifications. US-guided vacuum-assisted 
biopsy is known to be an effective alternative to stereotactic-guided 
vacuum-assisted biopsy in cases where microcalcifications are visible 
with the use of high-resolution US [25]. In our study, VABB was 
performed in 383 cases with microcalcifications and 107 cases (28%) 
were category 4b, 4c, and 5. Accordingly, the PPV was very high, at 
41%.
US-guided VABB is known to be a safe and effective method 
for complete excision of benign symptomatic lesions [4,26]. The 
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